Outcome of bone marrow transplantation from HLA-identical sibling donor in children with hematological malignancies using methotrexate alone as prophylaxis for graft-versus-host disease

Nobuhiro Watanabe, Kimikazu Matsumoto, Ayami Yoshimi, Keizo Horibe, Takaharu Matsuyama, Seiji Kojima, Koji Kato

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Most previous studies of graft-versus-host disease (GVHD) prophylaxis with methotrexate (MTX) alone in patients undergoing HLA-identical sibling donor bone marrow transplantation were performed in adults. With this background, we attempted to analyze the incidence and risk factors of GVHD in bone marrow transplantation (BMT) from an HLA-identical sibling donor in children with hematological malignancies using MTX alone as a prophylaxis for GVHD. Ninety-four patients received MTX by intravenous bolus injection, with a dose of 15 mg/m2 on day +1, followed by 10 mg/m2 on days +3, +6, and +11, and then weekly until day +60. The probability of developing grade II-IV acute GVHD and chronic GVHD was 19.1 and 31.8%, respectively. Age at transplantation and a female donor to male recipient were identified as risk factors for chronic GVHD in multivariate analysis, but no factors were identified for acute GVHD. The cumulative incidence of transplant-related mortality during the first 100 days was 9.6%. Disease-free survival at 5 years for standard- and high-risk patients was 82.1 and 39.5%, respectively. These results suggest that GVHD prophylaxis with MTX alone is safe and effective in young children under 10 years old at transplantation and in a setting other than female donor to male recipient.

Original languageEnglish
Pages (from-to)575-582
Number of pages8
JournalInternational journal of hematology
Volume88
Issue number5
DOIs
Publication statusPublished - Dec 1 2009
Externally publishedYes

Fingerprint

Graft vs Host Disease
Hematologic Neoplasms
Bone Marrow Transplantation
Methotrexate
Siblings
Tissue Donors
Transplantation
Incidence
Intravenous Injections
Disease-Free Survival
Multivariate Analysis
Transplants
Mortality

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Outcome of bone marrow transplantation from HLA-identical sibling donor in children with hematological malignancies using methotrexate alone as prophylaxis for graft-versus-host disease. / Watanabe, Nobuhiro; Matsumoto, Kimikazu; Yoshimi, Ayami; Horibe, Keizo; Matsuyama, Takaharu; Kojima, Seiji; Kato, Koji.

In: International journal of hematology, Vol. 88, No. 5, 01.12.2009, p. 575-582.

Research output: Contribution to journalArticle

Watanabe, Nobuhiro ; Matsumoto, Kimikazu ; Yoshimi, Ayami ; Horibe, Keizo ; Matsuyama, Takaharu ; Kojima, Seiji ; Kato, Koji. / Outcome of bone marrow transplantation from HLA-identical sibling donor in children with hematological malignancies using methotrexate alone as prophylaxis for graft-versus-host disease. In: International journal of hematology. 2009 ; Vol. 88, No. 5. pp. 575-582.
@article{3deae6d8eed14eca80c5e3a2b6ec4228,
title = "Outcome of bone marrow transplantation from HLA-identical sibling donor in children with hematological malignancies using methotrexate alone as prophylaxis for graft-versus-host disease",
abstract = "Most previous studies of graft-versus-host disease (GVHD) prophylaxis with methotrexate (MTX) alone in patients undergoing HLA-identical sibling donor bone marrow transplantation were performed in adults. With this background, we attempted to analyze the incidence and risk factors of GVHD in bone marrow transplantation (BMT) from an HLA-identical sibling donor in children with hematological malignancies using MTX alone as a prophylaxis for GVHD. Ninety-four patients received MTX by intravenous bolus injection, with a dose of 15 mg/m2 on day +1, followed by 10 mg/m2 on days +3, +6, and +11, and then weekly until day +60. The probability of developing grade II-IV acute GVHD and chronic GVHD was 19.1 and 31.8{\%}, respectively. Age at transplantation and a female donor to male recipient were identified as risk factors for chronic GVHD in multivariate analysis, but no factors were identified for acute GVHD. The cumulative incidence of transplant-related mortality during the first 100 days was 9.6{\%}. Disease-free survival at 5 years for standard- and high-risk patients was 82.1 and 39.5{\%}, respectively. These results suggest that GVHD prophylaxis with MTX alone is safe and effective in young children under 10 years old at transplantation and in a setting other than female donor to male recipient.",
author = "Nobuhiro Watanabe and Kimikazu Matsumoto and Ayami Yoshimi and Keizo Horibe and Takaharu Matsuyama and Seiji Kojima and Koji Kato",
year = "2009",
month = "12",
day = "1",
doi = "10.1007/s12185-008-0211-3",
language = "English",
volume = "88",
pages = "575--582",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - Outcome of bone marrow transplantation from HLA-identical sibling donor in children with hematological malignancies using methotrexate alone as prophylaxis for graft-versus-host disease

AU - Watanabe, Nobuhiro

AU - Matsumoto, Kimikazu

AU - Yoshimi, Ayami

AU - Horibe, Keizo

AU - Matsuyama, Takaharu

AU - Kojima, Seiji

AU - Kato, Koji

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Most previous studies of graft-versus-host disease (GVHD) prophylaxis with methotrexate (MTX) alone in patients undergoing HLA-identical sibling donor bone marrow transplantation were performed in adults. With this background, we attempted to analyze the incidence and risk factors of GVHD in bone marrow transplantation (BMT) from an HLA-identical sibling donor in children with hematological malignancies using MTX alone as a prophylaxis for GVHD. Ninety-four patients received MTX by intravenous bolus injection, with a dose of 15 mg/m2 on day +1, followed by 10 mg/m2 on days +3, +6, and +11, and then weekly until day +60. The probability of developing grade II-IV acute GVHD and chronic GVHD was 19.1 and 31.8%, respectively. Age at transplantation and a female donor to male recipient were identified as risk factors for chronic GVHD in multivariate analysis, but no factors were identified for acute GVHD. The cumulative incidence of transplant-related mortality during the first 100 days was 9.6%. Disease-free survival at 5 years for standard- and high-risk patients was 82.1 and 39.5%, respectively. These results suggest that GVHD prophylaxis with MTX alone is safe and effective in young children under 10 years old at transplantation and in a setting other than female donor to male recipient.

AB - Most previous studies of graft-versus-host disease (GVHD) prophylaxis with methotrexate (MTX) alone in patients undergoing HLA-identical sibling donor bone marrow transplantation were performed in adults. With this background, we attempted to analyze the incidence and risk factors of GVHD in bone marrow transplantation (BMT) from an HLA-identical sibling donor in children with hematological malignancies using MTX alone as a prophylaxis for GVHD. Ninety-four patients received MTX by intravenous bolus injection, with a dose of 15 mg/m2 on day +1, followed by 10 mg/m2 on days +3, +6, and +11, and then weekly until day +60. The probability of developing grade II-IV acute GVHD and chronic GVHD was 19.1 and 31.8%, respectively. Age at transplantation and a female donor to male recipient were identified as risk factors for chronic GVHD in multivariate analysis, but no factors were identified for acute GVHD. The cumulative incidence of transplant-related mortality during the first 100 days was 9.6%. Disease-free survival at 5 years for standard- and high-risk patients was 82.1 and 39.5%, respectively. These results suggest that GVHD prophylaxis with MTX alone is safe and effective in young children under 10 years old at transplantation and in a setting other than female donor to male recipient.

UR - http://www.scopus.com/inward/record.url?scp=64249089198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64249089198&partnerID=8YFLogxK

U2 - 10.1007/s12185-008-0211-3

DO - 10.1007/s12185-008-0211-3

M3 - Article

C2 - 19043808

AN - SCOPUS:64249089198

VL - 88

SP - 575

EP - 582

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 5

ER -